Xilio Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Xilio Therapeutics, Inc. - overview
Established
2016
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Established in 2016 and based in Massachusetts, US, Xilio Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapeutic products and tumor-selective therapies that overcome toxicities associated with validated IO therapies. The company was founded by Rene Russo (CEO). In February 2021, Xilio Therapeutics raised USD 95 million in series C funding from Atlas Venture, Bain Capital Life Sciences, Deerfield Management, MRL Ventures Fund, RA Capital Management, RiverVest Ventures, Rock Springs Capital, SV Health Investors, and Takeda Ventures.
In October 2021, the company got listed on Nasdaq Global Select Market under the ticker symbol XLO. Xilio Therapeutics focuses on enhancing the lives of cancer patients by utilizing the immune system to create deep and long-lasting clinical responses. The company's line of products includes XTX202 (Tumor-selective IL-2 agonist), XTX301 (Tumor-selective IL-12), XTX401 (Tumor-selective IL-15), and XTX101 (Tumor-selective anti-CTLA-4 antibody). Xilio Therapeutics, Inc.
plans to use the funds to advance XTX202 and XTX101 into clinical development.
Current Investors
F-Prime Capital, Atlas Venture, RiverVest Ventures Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.xiliotx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.